In particular, Lachmann and colleagues first showed that a median annual SAA concentration ≥ 155 mg/L in AA amyloidosis patients conferred a relative risk of death of 17.7 times higher than SAA titer < 4 mg/L in patients with more effective control of inflammation (95% CI 8.4–36.0, p > 0.001). Here, SAA2 is linked to AA amyloidosis.